Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06547255
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-07
Brief Title:
Exparel Versus Bupivacaine in Post-operative Pain Control
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Exparel Versus Bupivacaine in Post-operative Pain Control Following Bilateral Third Molar Extractions a Single-blind Randomized Clinical Trial
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a prospective randomized study to evaluate anaesthetic parameters postoperative analgesia and oral analgesic consumption comparing exparel liposomal bupivacaine vs standard bupivacaine
Detailed Description:
The main purpose of this prospective randomized study was to evaluate anaesthetic parameters postoperative analgesia and oral analgesic consumption comparing exparel liposomal bupivacaine vs standard bupivacaine At the end of the third molar extraction surgical procedure and at least fifteen minutes following the most recent administration of 2 lidocaine with 1100000 epinephrine routine for this procedure patients will at random receive mandibular and maxillary infiltrations with 3mL of 13 liposomal bupivacaine Exparel or with standard 3mL standard bupivacaine Electronic home questionnaires will be completed by the patient following the procedure for 96 hours to evaluate these clinical parameters
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None